Showing 1 - 9 results of 9 for search 'Jamey P. Weichert', query time: 0.04s Refine Results
  1. 1
    Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

    Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment by Caroline P. Kerr, Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert, Zachary S. Morris

    Published 2022-12-01
    Get full text
    Article
  2. 2
    Effect of Polar Head Group Modifications on the Tumor Retention of Phospholipid Ether Analogs: Role of the Quaternary Nitrogen

    Effect of Polar Head Group Modifications on the Tumor Retention of Phospholipid Ether Analogs: Role of the Quaternary Nitrogen by Anatoly N. Pinchuk, Mark A. Rampy, Marc A. Longino, Ben Y. Durkee, Raymond E. Counsell, Jamey P. Weichert

    Published 2023-01-01
    Get full text
    Article
  3. 3
    Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors

    Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90Y-NM600 in combination with androgen deprivation therapy in murine prostate... by Douglas G McNeel, Zachary S Morris, Reinier Hernandez, Jamey P Weichert, Anusha Muralidhar, Hansel Comas Rojas, Malick Bio Idrissou

    Published 2024-04-01
    Get full text
    Article
  4. 4
    mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.

    mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. by Dustin A Deming, Alyssa A Leystra, Mohammed Farhoud, Laura Nettekoven, Linda Clipson, Dawn Albrecht, Mary Kay Washington, Ruth Sullivan, Jamey P Weichert, Richard B Halberg

    Published 2013-01-01
    Get full text
    Article
  5. 5
    A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.

    A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. by Joseph J Grudzinski, Benjamin Titz, Kevin Kozak, William Clarke, Ernest Allen, LisaAnn Trembath, Michael Stabin, John Marshall, Steve Y Cho, Terence Z Wong, Joanne Mortimer, Jamey P Weichert

    Published 2014-01-01
    Get full text
    Article
  6. 6
    Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

    Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors by Douglas G McNeel, Hemanth K Potluri, Ohyun Kwon, Joseph Grudzinski, Christopher Massey, Reinier Hernandez, Carolina A Ferreira, Eduardo Aluicio-Sarduy, Jonathan W Engle, Ian R Marsh, Bryan P Bednarz, Jamey P Weichert

    Published 2022-08-01
    Get full text
    Article
  7. 7
    Phospholipid ether analogs for the detection of colorectal tumors.

    Phospholipid ether analogs for the detection of colorectal tumors. by Dustin A Deming, Molly E Maher, Alyssa A Leystra, Joseph P Grudzinski, Linda Clipson, Dawn M Albrecht, Mary Kay Washington, Kristina A Matkowskyj, Lance T Hall, Sam J Lubner, Jamey P Weichert, Richard B Halberg

    Published 2014-01-01
    Get full text
    Article
  8. 8
    Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination

    Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination by Zachary S Morris, Paul M Sondel, Amy K Erbe, Alexander L Rakhmilevich, Amber M Bates, Peter M Carlson, Alexander A Pieper, Ravi B Patel, Jen Birstler, Joseph Grudzinski, Reinier Hernandez, Bryan P Bednarz, Jamey P Weichert, Arika S Feils, Matthew Rodriquez, Claire Sun, Ian Marsh

    Published 2023-01-01
    Get full text
    Article
  9. 9
    Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.

    Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. by Kara Magee, Ian R Marsh, Michelle M Turek, Joseph Grudzinski, Eduardo Aluicio-Sarduy, Jonathan W Engle, Ilene D Kurzman, Cindy L Zuleger, Elizabeth A Oseid, Christine Jaskowiak, Mark R Albertini, Karla Esbona, Bryan Bednarz, Paul M Sondel, Jamey P Weichert, Zachary S Morris, Reinier Hernandez, David M Vail

    Published 2021-01-01
    Get full text
    Article

Search Tools: